CA2125060A1 - Ophthalmic Solution for Artificial Tears - Google Patents

Ophthalmic Solution for Artificial Tears

Info

Publication number
CA2125060A1
CA2125060A1 CA2125060A CA2125060A CA2125060A1 CA 2125060 A1 CA2125060 A1 CA 2125060A1 CA 2125060 A CA2125060 A CA 2125060A CA 2125060 A CA2125060 A CA 2125060A CA 2125060 A1 CA2125060 A1 CA 2125060A1
Authority
CA
Canada
Prior art keywords
ophthalmic solution
solution
artificial tears
preferably less
ophthalmic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CA2125060A
Other languages
French (fr)
Other versions
CA2125060C (en
Inventor
Henry P. Dabrowski
Anil Salpekar
O. William Lever Jr.
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bausch and Lomb Inc
Original Assignee
Bausch and Lomb Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bausch and Lomb Inc filed Critical Bausch and Lomb Inc
Publication of CA2125060A1 publication Critical patent/CA2125060A1/en
Application granted granted Critical
Publication of CA2125060C publication Critical patent/CA2125060C/en
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears

Abstract

An ophthalmic artificial tear solution is described for treating irritation and dryness of the eyes with a formulation that includes polyvinylpyrrolidone, a preservative such as benzalkonium chloride, glycerin and hydroxypropyl methylcellulose, wherein the composition is an aqueous solution having isotonic properties with respect to the eye. The ophthalmic solution of the invention is characterized as having a low viscosity, preferably less than 5 cps, and a low surface tension, preferably less than 40 dynes/cm, wherein wettability, retainability and comfort of the user are enhanced.
CA002125060A 1993-07-02 1994-06-03 Ophthalmic solution for artificial tears Expired - Fee Related CA2125060C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US8642193A 1993-07-02 1993-07-02
US08/086,421 1993-07-02

Publications (2)

Publication Number Publication Date
CA2125060A1 true CA2125060A1 (en) 1995-01-03
CA2125060C CA2125060C (en) 1999-03-30

Family

ID=22198460

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002125060A Expired - Fee Related CA2125060C (en) 1993-07-02 1994-06-03 Ophthalmic solution for artificial tears

Country Status (4)

Country Link
US (1) US5591426A (en)
BR (1) BR9402201A (en)
CA (1) CA2125060C (en)
MX (1) MX9405006A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511949B1 (en) 1996-02-07 2003-01-28 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition with regulated viscosity

Families Citing this family (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0880351A4 (en) * 1996-02-14 2003-01-08 Alcon Lab Inc Polymeric quaternary ammonium compounds and their use as ophthalmic antimicrobials
CN1230882A (en) * 1996-09-20 1999-10-06 博士伦公司 Method and composition for rewetting contact lenses and relieving eye dryness
US5800807A (en) * 1997-01-29 1998-09-01 Bausch & Lomb Incorporated Ophthalmic compositions including glycerin and propylene glycol
WO1999027060A1 (en) 1997-11-26 1999-06-03 Allergan Sales, Inc. Contact lens cleaning compositions
US6063745A (en) 1997-11-26 2000-05-16 Allergan Mutli-purpose contact lens care compositions
US6274626B1 (en) * 1998-12-22 2001-08-14 Bausch & Lomb Incorporated Pheniramine-containing compositions and method for treating allergic responses
AR022119A1 (en) * 1998-12-22 2002-09-04 Bausch & Lomb COMPOSITIONS CONTAINING PHENIRAMINE AND METHOD FOR THE TREATMENT OF ALLERGY RESPONSES
US8889112B2 (en) * 1999-09-16 2014-11-18 Ocularis Pharma, Llc Ophthalmic formulations including selective alpha 1 antagonists
US6730065B1 (en) * 2000-09-15 2004-05-04 Ocularis Pharma, Inc. Night vision composition
US6420407B1 (en) 1999-09-16 2002-07-16 Gerald Horn Ophthalmic formulation which modulates dilation
US20020082288A1 (en) * 1999-09-16 2002-06-27 Gerald Horn Ophthalmic formulations comprising an imidazoline
US20070104798A1 (en) 1999-10-04 2007-05-10 S.K. Pharmaceuticals, Inc. Synergistic antimicrobial preparations containing chlorite and hydrogen peroxide
KR20020069224A (en) * 1999-12-27 2002-08-29 산텐 세이야꾸 가부시키가이샤 System for stabilizing lacrimal fluid layer
JP4618443B2 (en) * 1999-12-27 2011-01-26 参天製薬株式会社 Tear fluid stabilization system
JP3846537B2 (en) * 1999-12-28 2006-11-15 ライオン株式会社 Contact lens mounting solution
WO2001097852A1 (en) * 2000-06-19 2001-12-27 Santen Pharmaceutical Co., Ltd. Aseptics
US20060211753A1 (en) * 2000-11-03 2006-09-21 Ocularis Pharma, Inc. Method and composition which reduces stimulation of muscles which dilate the eye
US9308264B2 (en) * 2000-11-08 2016-04-12 Fxs Ventures, Llc Ophthalmic contact lens solutions containing forms of vitamin B
US6703039B2 (en) * 2000-12-06 2004-03-09 Bausch & Lomb Incorporated Reversible gelling system for ocular drug delivery
US20030133905A1 (en) * 2001-12-20 2003-07-17 Zhenze Hu Composition for treating contact lenses in the eye
US20090215735A1 (en) * 2002-02-25 2009-08-27 Alcon, Inc. Topical solution formulations containing a corticosteroid and a cyclodextrin
JP2006504701A (en) * 2002-09-30 2006-02-09 マーク・エー・バビザイェフ Method for local treatment of eye diseases, therapeutic composition and therapeutic means thereof
CA2535029C (en) 2003-08-07 2013-07-16 Healor Ltd. Pharmaceutical compositions and methods for accelerating wound healing
ES2331890T3 (en) * 2004-03-18 2010-01-19 R-Tech Ueno, Ltd. AQUOUS COMPOSITION THAT INCLUDES A DERIVATIVE OF TIAZOL.
US7169881B2 (en) * 2004-10-29 2007-01-30 Clariant (France) Aminoplast resin compositions
US8703198B2 (en) * 2005-03-02 2014-04-22 Aquatrove Biosciences Water-based personal moisturizers and lubricants, in particular vaginal lubricants, and uses thereof
US20100233295A1 (en) * 2005-03-02 2010-09-16 Vibha Gupta Aqueous moisturizers and lubricants and uses thereof
EP1893164A2 (en) * 2005-06-20 2008-03-05 Playtex Products, Inc. Non-irritating compositions
ZA200802546B (en) * 2005-08-29 2009-10-28 Healor Ltd Methods and compositions for prvention and treatment of diabetic and aged skin
EP2319517B1 (en) * 2006-06-01 2013-09-11 Novagali Pharma S.A. Use of prodrugs for ocular intravitreous administration
AU2008281374B2 (en) * 2007-07-30 2012-05-31 Healor Ltd. Pharmaceutical composition for treating wounds and related methods
US8435544B2 (en) 2007-10-08 2013-05-07 Lux Biosciences, Inc. Ophthalmic compositions comprising calcineurin inhibitors or mTOR inhibitors
KR101805852B1 (en) * 2007-12-04 2018-01-10 산텐 에스에이에스 Cationic oil-in-water emulsion for ophthalmic topical administration of dexamethasone prodrug
WO2010144194A1 (en) * 2009-06-09 2010-12-16 Lux Biosciences, Inc. Topical drug delivery systems for ophthalmic use
WO2011083483A2 (en) 2010-01-11 2011-07-14 Healor Ltd. Method for treatment of inflammatory disease and disorder
US20120264681A1 (en) 2010-11-08 2012-10-18 Healor Ltd. Buffered ophthalmic compositions and methods of use thereof
TWI544922B (en) 2011-05-19 2016-08-11 愛爾康研究有限公司 High concentration olopatadine ophthalmic composition
ES2835398T3 (en) 2013-02-01 2021-06-22 Ocuphire Pharma Inc Methods and compositions for daily ophthalmic administration of phentolamine to improve visual performance
ES2762153T3 (en) 2013-02-01 2020-05-22 Ocuphire Pharma Inc Aqueous phentolamine ophthalmic solutions and medical uses thereof
RU2537034C1 (en) * 2013-11-29 2014-12-27 Закрытое акционерное общество "ФИРН М" (ЗАО "ФИРН М") Therapeutic agent for oral cleaning in individuals suffering xerostomia, possessing antiseptic action as spray, gel and mouthwash
SG11201704010UA (en) 2014-08-20 2017-06-29 Silk Tech Ltd Fibroin-derived protein composition
CN105749360B (en) * 2016-03-28 2019-06-18 赛克赛斯生物科技股份有限公司 A kind of composition and the preparation method and application thereof for protecting cornea
WO2017200659A2 (en) 2016-04-08 2017-11-23 Cornell University A method to enhance wound healing using silk-derived protein
WO2018031973A1 (en) 2016-08-12 2018-02-15 Silk Technologies, Ltd. Silk-derived protein for treating inflammation
WO2018199180A1 (en) * 2017-04-25 2018-11-01 わかもと製薬株式会社 Thermogelling artificial tears
US20190224275A1 (en) 2017-05-12 2019-07-25 Aurinia Pharmaceuticals Inc. Protocol for treatment of lupus nephritis
AU2019366451A1 (en) 2018-10-26 2021-05-20 Ocuphire Pharma, Inc. Methods and compositions for treatment of presbyopia, mydriasis, and other ocular disorders
CN114286670B (en) * 2019-08-27 2024-01-16 参天制药株式会社 Aqueous ophthalmic composition containing diquafosol or a salt thereof and polyvinylpyrrolidone
CN115368310A (en) 2021-05-18 2022-11-22 奥库菲尔医药公司 Method for synthesizing phentolamine mesylate

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3311577A (en) * 1965-03-29 1967-03-28 Burton Parsons Chemicals Inc Underwater contact lens solution
US3549747A (en) * 1968-02-20 1970-12-22 Flow Pharma Inc Contact lens wetting solution and method of using same
US3947573A (en) * 1969-12-01 1976-03-30 Burton, Parsons And Company, Inc. Opthalmic solution
US3856919A (en) * 1970-06-08 1974-12-24 Burton Parsons Chemicals Inc Ophthalmic solution
US3987163A (en) * 1973-07-27 1976-10-19 Burton, Parsons And Company, Inc. Polystyrene sulfonate containing opthalmic solutions
US4029817A (en) * 1973-09-24 1977-06-14 Allergan Pharmaceuticals Soft contact lens preserving solutions
US4013576A (en) * 1973-11-21 1977-03-22 Wesley-Jessen Inc. Contact lens treating composition
US3920810A (en) * 1974-04-23 1975-11-18 Burton Parsons And Company Inc Polyacrylamide containing ophthalmic solutions
US4039662A (en) * 1975-12-04 1977-08-02 Alcon Laboratories, Inc. Ophthalmic solution
US4120949A (en) * 1977-10-05 1978-10-17 Cooper Laboratories, Inc. Ophthalmic solution
US4438123A (en) * 1980-03-04 1984-03-20 Merck & Co., Inc. Ophthalmic compositions of carbonic anhydrase inhibitors for topical application in the treatment of elevated intraocular pressure
US4432964A (en) * 1981-08-24 1984-02-21 Alza Corporation Topical composition containing steroid in two forms released independently from polymeric carrier
US4626292A (en) * 1982-06-01 1986-12-02 Sherman Laboratories, Inc. Soft contact lens wetting and preservation method
US4421748A (en) * 1982-07-13 1983-12-20 Trager Seymour F Artificial tear aid
US4470965A (en) * 1982-10-27 1984-09-11 Usv Pharmaceutical Corporation Celiprolol for the treatment of glaucoma
US4744980A (en) * 1986-04-28 1988-05-17 Holly Frank J Ophthalmic solution for treatment of dry eye syndrome
IL80298A (en) * 1986-10-14 1993-01-31 Res & Dev Co Ltd Eye drops
US5141665A (en) * 1987-03-31 1992-08-25 Sherman Laboratories, Inc. Cleaning, conditioning, storing and wetting system and method for rigid gas permeable contact lenses and other contact lenses
EP0389995B1 (en) * 1989-03-28 1995-05-31 Nisshin Flour Milling Co., Ltd. Isoquinoline derivatives for the treatment of glaucoma or ocular hypertension
US5264449A (en) * 1989-11-13 1993-11-23 Allergan, Inc. N-substituted derivatives of 3R,4R-ethyl-[(1-methyl-1H-imidazol-5-yl)methyl]-2-pyrrolidinone

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6511949B1 (en) 1996-02-07 2003-01-28 Rohto Pharmaceutical Co., Ltd. Ophthalmic composition with regulated viscosity

Also Published As

Publication number Publication date
CA2125060C (en) 1999-03-30
US5591426A (en) 1997-01-07
BR9402201A (en) 1995-03-14
MX9405006A (en) 1995-01-31

Similar Documents

Publication Publication Date Title
CA2125060A1 (en) Ophthalmic Solution for Artificial Tears
CA2236582A1 (en) Substituted tetrahydrofuran analogs of prostaglandins as ocular hypotensives
CA2193543A1 (en) Sodium hyaluronate based ophthalmic formulation for use in eye surgery
BR0013255A (en) Tear replacement agent
AU1387088A (en) Use of a prostaglandin in combination with an adrenergic blocking agent for reduction of intraocularpressure
MX9702349A (en) Use of 9-deoxy prostaglandin derivatives to treat glaucoma.
CA2433849A1 (en) Glaucoma treatment device and method
EP0879601A3 (en) Ophthalmic drug delivery system
CA2280089A1 (en) Compositions and methods for reducing ocular hypertension
CA2436269A1 (en) Artificial tear composition containing a combination of three demulcents
WO2000018316A3 (en) Sustained release, and comfortable ophthalmic composition and method for ocular therapy
WO1998039293A3 (en) 13-thia prostaglandins for use in glaucoma therapy
WO2002049611A3 (en) Ophthalmic lubricating solution adapted for use in lasik surgery
GR3032701T3 (en) Ophthalmic gel.
NO950595D0 (en) Ophthalmological preparation
KR20020069224A (en) System for stabilizing lacrimal fluid layer
CA2306371A1 (en) Use of flunarizine for the topical treatment of glaucoma
EP0349487A3 (en) Antimicrobial ophthalmic solutions containing dodecyl-dimethyl-(2-phenoxyethyl)-ammonium bromide and methods of using the same
CA2307303A1 (en) Prolonged-action eye drop
RU93043496A (en) MEANS OF ANTIOXIDANT PROTECTION OF ENVIRONMENT AND FABRIC EYE
ES2088489T3 (en) USE OF PROSTAGLANDINE F3ALFA AS A HYPOTENSIVE EYE AGENT.

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed
MKLA Lapsed

Effective date: 20030602